Resistance | All isolates | Sampled clinical cases | |||
---|---|---|---|---|---|
Total | CABSI | HABSI | P value a | ||
Any extended spectrum cephalosporin | 19/133 (14.3%) | 13/112 (11.6%) | 8/90 (8.9%) | 5/22 (22.7%) | 0.128 |
ESBL production | 15/122 (12.3%) | 9/101 (8.9%) | 5/82 (6.1%) | 4/19 (21.1%) | 0.062 |
Others | 4/133 (3.0%) | 4/112 (3.6%) | 3/90 (3.3%) | 1/22 (4.5%) | 1 |
Any carbapenem | 1/131 (0.8%) | 1/109 (0.9%) | 0/89 (0%) | 1/20 (5%) | 0.183 |
Any aminoglycoside | 17/131 (13.0%) | 13/109 (11.9%) | 9/89 (10.1%) | 4/20 (20%) | 0.252 |
Any fluoroquinolone | 11/131 (8.4%) | 8/109 (7.3%) | 4/89 (4.5%) | 4/20 (20%) | 0.036 |
Co-trimoxazole | 24/124 (19.4%) | 19/102 (18.6%) | 14/84 (16.7%) | 5/18 (27.8%) | 0.318 |